ERBB2 and breast carcinoma: FDA approval was granted for talazoparib's use in adult patients with germline breast cancer mutation (gBRCAm) HER2-negative locally advanced or metastatic breast cancer, based on findings from the phase III EMBRACA trial (NCT01945775).